ClinicalTrials.gg
CompletedNCT00327444Updated Jan 1, 2013Results posted

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

A Phase 2/3 interventional study of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Placebo in Ovarian Neoplasms and Ascites, sponsored by Sanofi. Completed at 9 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-01.

Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Ovarian Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Ovarian Neoplasms · Sanofi.

Enrollment
4th of 13
58 · median 47
Started
2006
with 3 others
Phase 2/3
Only one
of the 14
Registered
3rd of 14
by date

Among the 14 studies in Ovarian Neoplasms by Sanofi, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is the only one in phase 2/3, and was the 3rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 14 studies in Ovarian Neoplasms by Sanofi is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Ovarian Neoplasms by Sanofi as a file.
02

Study summary

This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.

Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer

Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.

Read the detailed description

The study included:

  • A Thirty (30)-day screening phase
  • The double blind treatment period for a minimum of 60 days. Day 1 of the double-blind treatment period was defined as the date of the qualifying paracentesis (ie, withdrawal of >= 1 Liter of ascitic fluid). Participants were randomized after adequate recovery from the qualifying paracentesis (The first dose was administered on Day 1 or Day 2).
  • The optional open-label extension (until treatment discontinuation criteria were met)
  • A posttreatment follow-up phase lasting 60 days.

Criteria for discontinuation included:

  1. Participant or his legally authorized representative request discontinuation
  2. In the Investigator's opinion, continuation of treatment would be detrimental to the participant's well being, such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations
  3. Sponsor request
  4. Intercurrent illness that prevented further administration of investigational product(IP)
  5. More than 2 IP dose reductions
  6. Unacceptable adverse events (AE) not manageable by symptomatic therapy, dose delay, or dose modification
  7. Arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of preexisting angina
  8. Radiographic evidence of intestinal obstruction (for example, dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (for example, presence of extraluminal gas) requiring surgical intervention
03

Conditions studied

  • Ovarian Neoplasms
  • Ascites

Keywords

  • Ovarian neoplasm
  • Ascites
  • Angiogenesis inhibitor
  • Vascular Endothelial Growth Factor A
  • Recombinant fusion protein
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants who met the following criteria were eligible to participate in this study.

Inclusion criteria

Inclusion Criteria:

  • Advanced ovarian epithelial cancer, treated with paracentesis
  • Platinum-resistant, and topotecan-resistant and/or liposomal doxorubicin-resistant disease;
  • (ECOG) performance status =\< 2.

Exclusion criteria

Exclusion Criteria:

  • Pseudomyxoma peritonei or peritoneal mesothelioma;
  • Transudative ascites;
  • Peritoneovenous or other shunt placed for malignant ascites management;
  • Recent (\<6 months) cardiovascular event (pulmonary embolus, myocardial infarction, stroke) or gastrointestinal disease (ulcer, hepatic cirrhosis);
  • Known ;
  • Uncontrolled hypertension;
  • Recent treatment with chemotherapy, surgery or radiotherapy;
  • Prior treatment with VEGF or VEGFR inhibitor.

The above information is not intended to contain all considerations relevant to participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period. In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study.

    Drug: Placebo · Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

  • Experimental
    Aflibercept

    Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period. In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study.

    Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Repeat Paracentesis (TRP)

    TRP was defined as the number of days between the date of randomization and the date of the first post-randomization paracentesis. For participants who did not undergo a postrandomization paracentesis on study, TRP was calculated from randomization to the end of the double-blind treatment period.

    Time frame: From Day 1 up to 6 months from randomization

Secondary outcomes

  1. Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)

    AIM 4 symptoms (abdominal discomfort, abdominal bloating, abdominal pain, and ability to move normally) are scored from 0 to 5, where higher scores represent worst outcomes. An AIM total score ranges from 0-20. A plot for (The AIM questionnaire total score - Baseline score) versus time were generated. AIM AUC represents the overall improvement (scored positive) if the area is below the baseline value or worsening (scored negative) if the area is above the baseline. AIM AUC for a participant is the sum of individual areas representing improvement (+) or worsening (-).

    Time frame: From Day 1 up to 60 days from randomization to the first postrandomization paracentesis

  2. 60-Day Frequency of Paracentesis (FOP)

    60-Day FOP was defined as the total number of paracenteses performed within the first 60 days after randomization during the double blind treatment period.

    Time frame: From Day 1 up to 60 days from randomization

  3. Plasma Levels of Free and VEGF-bound Aflibercept

    Free aflibercept and VEGF-bound aflibercept plasma concentrations were measured by separate enzyme-linked immunosorbent assay (ELISA). The limit of quantitation of free aflibercept was 15.6 ng/mL, and of VEGF-bound aflibercept was 43.9 ng/mL. Peak free aflibercept was estimated at the end of Cycle 1 (C1) administration. The median free and VEGF-bound trough concentrations were determined for each participant beyond Cycle 3 (C3), then mean values were estimated from these median values.

    Time frame: Following every biweekly treatment administration up to 60 days after treatment discontinuation

07

Results

Posted Jan 1, 2013

Participant flow

Fifty-eight (58) participants from a total of 23 sites in 7 countries were enrolled in the study.

Double Blind Treatment (DB) Period
Participant flow — Double Blind Treatment (DB) Period
MilestonePlaceboAflibercept
Started2629
Safety2530
Completed00
Not completed2629
Withdrew: Disease progression1013
Withdrew: Adverse event55
Withdrew: Subject request01
Withdrew: Withdrew db and continued to ol1110
Open Label Treatment (OL) Period
Participant flow — Open Label Treatment (OL) Period
MilestonePlaceboAflibercept
Started1110
Ongoing treatment10
Completed00
Not completed1110
Withdrew: Disease progression87
Withdrew: Adverse event22
Withdrew: Worsening dyspnea01
Withdrew: Ongoing treatment10

Outcome measures

PrimaryTime to Repeat Paracentesis (TRP)

TRP was defined as the number of days between the date of randomization and the date of the first post-randomization paracentesis. For participants who did not undergo a postrandomization paracentesis on study, TRP was calculated from randomization to the end of the double-blind treatment period.

Time frame:
From Day 1 up to 6 months from randomization
Reported as:
Least squares mean · days
Time to Repeat Paracentesis (TRP)
daysPlaceboAflibercept
Time to Repeat Paracentesis (TRP)23.3 ± 7.7055.1 ± 7.25
Statistical analysis
  • Placebo vs Aflibercept · ANOVA · p = 0.0019 (Estimated using Wilcoxon rank-sum test with stratification of baseline paracentesis (=\<2 weeks versus \>2 weeks) at randomization.) · Least squares (ls) mean difference: 31.8 · 95% CI 10.56 to 53.05The LS mean difference is estimated for aflibercept versus placebo (aflibercept-placebo).
SecondaryArea Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)

AIM 4 symptoms (abdominal discomfort, abdominal bloating, abdominal pain, and ability to move normally) are scored from 0 to 5, where higher scores represent worst outcomes. An AIM total score ranges from 0-20. A plot for (The AIM questionnaire total score - Baseline score) versus time were generated. AIM AUC represents the overall improvement (scored positive) if the area is below the baseline value or worsening (scored negative) if the area is above the baseline. AIM AUC for a participant is the sum of individual areas representing improvement (+) or worsening (-).

Time frame:
From Day 1 up to 60 days from randomization to the first postrandomization paracentesis
Reported as:
Least squares mean · (units on a 4-symptom scale)*day
Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)
(units on a 4-symptom scale)*dayPlaceboAflibercept
Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)29.8 ± 148.07405.3 ± 143.21
Statistical analysis
  • Placebo vs Aflibercept · ANOVA · p = 0.0160 (Estimated using Wilcoxon rank-sum test with stratification of baseline paracentesis (=\<2 weeks versus \>2 weeks) at randomization.) · Least squares (ls) mean difference: 375.5 · 95% CI -46.48 to 797.42The LS mean difference was estimated for aflibercept versus placebo (aflibercept-placebo).
Secondary60-Day Frequency of Paracentesis (FOP)

60-Day FOP was defined as the total number of paracenteses performed within the first 60 days after randomization during the double blind treatment period.

Time frame:
From Day 1 up to 60 days from randomization
Reported as:
Least squares mean · paracentesis
60-Day Frequency of Paracentesis (FOP)
paracentesisPlaceboAflibercept
60-Day Frequency of Paracentesis (FOP)5.1 ± 0.692.7 ± 0.65
Statistical analysis
  • Placebo vs Aflibercept · ANOVA · p = 0.0035 (Estimated using Wilcoxon rank-sum test with stratification of baseline paracentesis (=\<2 weeks versus \>2 weeks) at randomization.) · Least squares (ls) mean difference: -2.4 · 95% CI -4.33 to -0.54The LS mean difference is estimated for aflibercept versus placebo (aflibercept-placebo).
SecondaryPlasma Levels of Free and VEGF-bound Aflibercept

Free aflibercept and VEGF-bound aflibercept plasma concentrations were measured by separate enzyme-linked immunosorbent assay (ELISA). The limit of quantitation of free aflibercept was 15.6 ng/mL, and of VEGF-bound aflibercept was 43.9 ng/mL. Peak free aflibercept was estimated at the end of Cycle 1 (C1) administration. The median free and VEGF-bound trough concentrations were determined for each participant beyond Cycle 3 (C3), then mean values were estimated from these median values.

Time frame:
Following every biweekly treatment administration up to 60 days after treatment discontinuation
Reported as:
Mean · μg/mL
Plasma Levels of Free and VEGF-bound Aflibercept
μg/mLDouble Blind (DB) PeriodOpen-Label (OL) Period
Peak Free Aflibercept (C1) (N=20, N=15)69.8 ± 29.762.1 ± 29.5
Trough Free Aflibercept (Beyond C3) (N=15, N=19)5.33 ± 3.675.10 ± 5.29
Trough Bound Aflibercept (Beyond C3) (N=16, N=17)3.02 ± 1.293.49 ± 1.48

Adverse events

Collected over From treatment initiation to October 30, 2009. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—18/25 (72%)22/25 (88%)
Aflibercept—27/30 (90%)28/30 (93.3%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventPlaceboAflibercept
Disease progressionGeneral disorders8/2510/30
VomitingGastrointestinal disorders3/256/30
DyspnoeaRespiratory, thoracic and mediastinal disorders1/256/30
DehydrationMetabolism and nutrition disorders4/254/30
Abdominal painGastrointestinal disorders0/253/30
Small intestinal obstructionGastrointestinal disorders1/253/30
AscitesGastrointestinal disorders2/251/30
Intestinal obstructionGastrointestinal disorders2/250/30
FatigueGeneral disorders2/250/30
Respiratory distressRespiratory, thoracic and mediastinal disorders2/251/30
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPlaceboAflibercept
VomitingGastrointestinal disorders13/2519/30
FatigueGeneral disorders14/2510/30
DiarrhoeaGastrointestinal disorders5/2512/30
Oedema peripheralGeneral disorders10/2511/30
NauseaGastrointestinal disorders9/2511/30
AnorexiaMetabolism and nutrition disorders9/258/30
DyspnoeaRespiratory, thoracic and mediastinal disorders9/256/30
CoughRespiratory, thoracic and mediastinal disorders3/258/30
AstheniaGeneral disorders3/257/30
Back painMusculoskeletal and connective tissue disorders4/257/30

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboAfliberceptTotal
< 35 years011
>=35 to <45 years516
>=45 to <55 years10717
>=55 to <65 years41115
>=65 to <75 years6713
>=75 years123
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAfliberceptTotal
Female262955
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAfliberceptTotal
Caucasian192241
Black101
Asian, Oriental6713
08

Study locations

9 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012 Feb;13(2):154-62. doi: 10.1016/S1470-2045(11)70338-2. Epub 2011 Dec 20. PubMed 22192729 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 3 years 3 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2006
First posted
May 18, 2006
Start
Jul 2006
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results delay requested
Jul 21, 2011
Results first posted
Jan 1, 2013
Last update
Jan 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00327444
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 18, 2006
Start date
Jul 2006
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jan 1, 2013
Last update
Jan 1, 2013

Study contacts

Walter GOTLIEB
principal investigator · Director of Gynecologic Oncology and Colposcopy Associate Professor of Oncology, McGill University - Montreal - Quebec Canada

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion